Marshall Wace, LLP Precigen, Inc. Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.41 - $2.79 $686,396 - $1.36 Million	486,806 New	486,806 $1.03 Million
Q2 2022 Aug 15, 2022	SELL	$1.15 - $2.53 $680,642 - $1.5 Million	-591,863 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.91 - $3.98 $1.1 Million - $2.29 Million	575,206 Added 3453.24%	591,863 $1.25 Million
Q4 2021 Feb 14, 2022	SELL	$3.53 - $5.5 $1.3 Million - $2.02 Million	-367,452 Reduced 95.66%	16,657 $62,000
Q3 2021 Nov 15, 2021	BUY	$4.99 - $6.55 $834,362 - $1.1 Million	167,207 Added 77.09%	384,109 $1.92 Million
Q2 2021 Aug 13, 2021	BUY	$6.24 - $8.22 $1.35 Million - $1.78 Million	216,902 New	216,902 $1.41 Million
Q3 2020 Nov 16, 2020	SELL	$3.5 - $6.2 $190,144 - $336,827	-54,327 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$2.16 - $5.46 $117,346 - $296,625	54,327 New	54,327 $271,000

142

159M

232K

69K

Ticker PGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 208,150,000
Market Cap $235M
Description
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.